In October 2013, the FDA approved labeling improvements for ezogabine, such as a boxed warning, emphasizing greater threats for likely everlasting adverse outcomes, such as retinal abnormalities, vision reduction, and skin discoloration. The agency proposed that using ezogabine be limited to individuals who may have had an inadequate response to nu… Read More